“我是股东”走进昆药集团：解码中医药企业的创新发展与战略蓝图

Core Insights - The event "I am a Shareholder - Visiting Listed Company Kun Pharmaceutical Group" showcased the company's innovative path, strategic layout, and industrial upgrade achievements, emphasizing its status as a top 100 pharmaceutical enterprise in China [1] Group 1: Cultural Heritage and Innovation - Investors experienced an immersive journey into traditional Chinese medicine culture at Kun Pharmaceutical's subsidiary Kun Traditional Chinese Medicine's museum and intangible cultural heritage experience center, highlighting the company's 640-year development in Yunnan [2] - The museum displayed historical documents, traditional pharmaceutical tools, and local medicinal materials, illustrating Kun Traditional Chinese Medicine's resource advantages in producing high-quality national medicines [2] - The integration of traditional craftsmanship with smart manufacturing was demonstrated, showcasing the preservation of traditional essence while enhancing production efficiency [2] Group 2: Strategic Dialogue and Industry Upgrades - The event featured a dialogue with key executives, including the Secretary-General of the Yunnan Listed Companies Association, emphasizing Kun Pharmaceutical's role as a representative of China's pharmaceutical industry transformation [3] - The company has developed a diversified business structure encompassing traditional Chinese medicine, chemical drugs, and pharmaceutical distribution, with a focus on health products for the aging population [3] Group 3: Investment Focus Areas - Investors expressed interest in three main areas: the silver economy, collaboration with China Resources Sanjiu, and globalization strategies [3] - Kun Pharmaceutical aims to deepen the "medical-nursing integration" model to cater to the growing elderly health market, enhancing product competitiveness through scientific research and rational medication guidance [3] - The company is accelerating its internationalization process, leveraging its global network resources, particularly in artemisinin, and has established sales networks in 60 countries [3] Group 4: Growth Potential and Resilience - An investor noted that Kun Pharmaceutical's strategic layout is both pragmatic and forward-looking, aligning with national policies and market demands, showcasing strong growth potential and resilience [4] Group 5: Conclusion - The event fostered a bridge of trust between industry and capital, highlighting Kun Pharmaceutical's goal of becoming a leader in the silver health industry while advancing its strategic blueprint for high-quality development in China's pharmaceutical sector [5]